Sign in
ABVX Stock Price, Chart, Stats & News
Abivax S.A.
Save
6.45B
Market cap
–
Current P/E
–
Forward P/E
ABVX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -2407.41% |
Pretax margin | -2075.06% |
Net margin | -2075.06% |
Effective tax rate | – |
ROA | -163.31% |
ROE | 5077.65% |
D/E | -1.75x |
Interest coverage ratio | -27.05x |
ABVX valuation
P/E | – |
P/S | 618.43x |
P/B | -116.64x |
P/CF | -41.56x |
P/FCF | -42.82x |
P/OCF | -41.56x |
PEG | 0.76x |
EV multiple | -25.71x |
About
Abivax S. A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19.
Similar securities
Based on sector and market capitalization
Report issue